MRK vs ABT
By Alex · Tickerpine
Merck & Co., Inc. vs Abbott Laboratories, side by side — the numbers that matter, in plain English. No “winner” hype; you decide.
| Metric | MRK | ABT |
|---|---|---|
| Price | $145.27 | $103.70 |
| Market cap | $358.41B | $179.44B |
| P/E ratio | 117.2 | 38.6 |
| ROE | 6.96% | — |
| Profit margin | 4.77% | 9.75% |
| Revenue growth | 5.10% | 14.50% |
| Dividend yield | 2.34% | 2.43% |
| Beta | 0.22 | 0.58 |
Green = the more favorable figure for that metric (lower P/E, higher ROE, margin, growth and yield). Not a recommendation.
MRK vs ABT in plain English
- MRK is the bigger company — about 2.0× the market cap of ABT.
- ABT is cheaper on earnings (P/E 38.6 vs 117.2).
- ABT is growing revenue faster (14% vs 5%).
- ABT has the higher dividend yield (2.43% vs 2.34%).
How would $1,000 have done in each?
MRK return calculator
See what $1,000 in Merck & Co., Inc. would be worth today.
ABT return calculator
See what $1,000 in Abbott Laboratories would be worth today.
Figures from public market data, may be delayed. Comparison is informational only — not investment advice.